Role of Multistrain Probiotics in Presentation of Severity and Frequency of Upper Respiratory Tract Infection

Dua  Akhtiar; Shaheen  Masood; Aamir  Nasruddin; Tayyaba  Anwer; Kiran  Memon; Taimur Naeem  Faridi

doi:10.54112/bcsrj.v6i2.1550

Authors

Dua Akhtiar Department of Pediatric Abbasi Shaheed Hospital Karachi, Pakistan
Shaheen Masood Department of Pediatric Abbasi Shaheed Hospital Karachi, Pakistan
Aamir Nasruddin Department of Pediatric Abbasi Shaheed Hospital Karachi, Pakistan
Tayyaba Anwer Department of Pediatric Abbasi Shaheed Hospital Karachi, Pakistan
Kiran Memon Department of Pediatric Abbasi Shaheed Hospital Karachi, Pakistan
Taimur Naeem Faridi Department of Pediatric Abbasi Shaheed Hospital Karachi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i2.1550

Keywords:

Probiotics Respiratory Tract Infections Immune System Inflammation Mediators Treatment Outcome

Abstract

Upper respiratory tract infections (URTIs) are a common health issue that significantly impact individuals’ quality of life. Probiotic supplementation has been suggested as a potential intervention to reduce URTIs’ frequency, severity, and duration. Objective: This study aimed to evaluate the role of multistrain probiotics in the presentation of severity and frequency of URTIs. Methods: This cross-sectional study was conducted at Abbasi Shaheed Hospital, Karachi, during July 2024 to December 2024. The study involved a total of 185 patients, aged between 4 and 12 years. Data collection was carried out in two phases: baseline and follow-up. At baseline, participants underwent a thorough medical examination and completed questionnaires assessing their general health and history of respiratory infections. Results: The treatment group experienced a significantly lower frequency of URTIs (1.14 episodes per participant) compared to the other group (2.03 episodes per participant, p < 0.01). Symptom severity, as indicated by the Jackson score, was significantly reduced in the probiotic group (2.3 ± 0.8) compared to the other group (3.4 ± 1.1, p < 0.05). The duration of illness was also shorter in the treatment group (4.5 ± 1.2 days) compared to the other group (6.2 ± 1.5 days, p < 0.01). Immune markers showed a favorable response in the probiotic group, with reduced IL-6 levels and increased IL-10. Conclusions: Multistrain probiotics significantly reduce the frequency, severity, and duration of URTIs. The probiotics also positively impact immune function and quality of life, with minimal side effects. These findings suggest that multistrain probiotics could be a helpful adjunct in preventing and reducing the severity of URTIs, particularly in individuals prone to recurrent infections.

Downloads

Download data is not yet available.

References

Khan Laghari, I., Nawaz, T., Mustafa, S., Jamali, A.A. and Fatima, S., 2023. Role of multi-strain probiotics in preventing severity and frequency of recurrent respiratory tract infections in children. BMC pediatrics, 23(1), p.505.

Tavares-Silva, Edgar, Aline Venticinque Caris, Samile Amorin Santos, Graziela Rosa Ravacci, and Ronaldo Vagner Thomatieli-Santos. "Effect of multi-strain probiotic supplementation on URTI symptoms and cytokine production by monocytes after a marathon race: a randomized, double-blind, placebo study." Nutrients 13, no. 5 (2021): 1478.

Sandionigi, Anna, Alessandra De Giani, Francesco Tursi, Angela Michelotti, Enza Cestone, Silvana Giardina, Jessica Zampolli, and Patrizia Di Gennaro. "Effectiveness of Multistrain Probiotic Formulation on Common Infectious Disease Symptoms and Gut Microbiota Modulation in Flu‐Vaccinated Healthy Elderly Subjects." BioMed research international 2022, no. 1 (2022): 3860896.

Darbandi, A., Asadi, A., Ghanavati, R., Afifirad, R., Emamie, A.D. and Talebi, M., 2021. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010–20. International Journal of Infectious Diseases, 105, pp.91-104.

Pico-Monllor, J.A., Ruzafa-Costas, B., Nunez-Delegido, E., Sanchez-Pellicer, P., Peris-Berraco, J. and Navarro-Lopez, V., 2021. Selection of probiotics in the prevention of respiratory tract infections and their impact on occupational health: scoping review. Nutrients, 13(12), p.4419.

Ouwehand AC, Invernici MM, Furlaneto FA, Messora MR. Effectiveness of multi-strain versus single-strain probiotics: current status and recommendations for the future. Journal of clinical gastroenterology. 2018 Nov 1;52:S35-40.

Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Ismail N, Matar C. Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders. Molecules. 2020 Oct 22;25(21):4891.

Giacchi, V., Sciacca, P. and Betta, P., 2016. Multistrain probiotics: the present forward the future. Probiotics, Prebiotics, and Synbiotics, 19, pp.279-302.

Garaiova, I., Paduchová, Z., Nagyová, Z., Wang, D., Michael, D.R., Plummer, S.F., Marchesi, J.R., Ďuračková, Z. and Muchová, J., 2021. Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial. Beneficial Microbes, 12(5), pp.431-440.

Timmerman, H.M., Koning, C.J., Mulder, L., Rombouts, F.M. and Beynen, A.C., 2004. Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy. International journal of food microbiology, 96(3), pp.219-233.

Singh S, Chauhan JP, Kumar V, Saxena R. ROLE OF PROBIOTICS IN THE PREVENTION OF RECURRENT ACUTE RHINOSINUSITIS. Int J Acad Med Pharm. 2024;6(6):518-21.

Yuksel N, Gelmez B, Yildiz-Pekoz A. Lung microbiota: its relationship to respiratory system diseases and approaches for lung-targeted probiotic bacteria delivery. Molecular Pharmaceutics. 2023 Jun 21;20(7):3320-37.

Lenoir-Wijnkoop I, Gerlier L, Roy D, Reid G. The clinical and economic impact of probiotics consumption on respiratory tract infections: projections for Canada. PLoS One. 2016 Nov 10;11(11):e0166232.

Spacova, I., De Boeck, I., Cauwenberghs, E., Delanghe, L., Bron, P.A., Henkens, T., Simons, A., Gamgami, I., Persoons, L., Claes, I. and van den Broek, M.F., 2023. Development of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections. Microbial Biotechnology, 16(1), pp.99-115.

Li, Y., Shi, X., Ma, T., Hu, W., Jin, H., Zhang, H., Liong, M.T. and Sun, Z., 2024. Bifidobacterium lactis Probio-M8 relieved acute respiratory tract infections in children possibly by modulating the gut microbes and metabolites. Journal of Functional Foods, 115, p.106111.